Dark

Check out our Dark Pool Levels

CNTA
Centessa Pharmaceuticals plc
stock NASDAQ

Inactive

Jun 23, 2026

40.50USD+0.796%(+0.32)11,330,437

Pre-market

0.00USD-100.000%(-40.18)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsTrends

CNTA Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

CNTA Specific Mentions

As of Jul 14, 2026 8:08:22 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

68 days ago • u/Complex-Jello-2031 • r/stockstobuytoday • drop_a_stock_you_think_everyone_should_buy • C

**The 2026 takeout scorecard, 10 deals, $41.6B**
New deal today
This is what consolidation looks like when it is real. Every one of these names was on the radar before the deal hit.
**CNTA to Lilly, $7.8 billion.** Radiopharmaceutical platform.
**OGN to Sun Pharma, $6.8 billion.** Women's health and biosimilars commercial portfolio, India-based acquirer.
**TERN to Merck, $6.7 billion.** Oral GLP-1 obesity asset.
**APLS to Biogen, $5.6 billion upfront.** Complement platform with SYFOVRE in geographic atrophy and EMPAVELI in PNH.
**CPRX to Angelini Pharma, $4.1 billion.** Rare disease commercial portfolio.
**SLNO to Neurocrine, $2.9 billion.** Prader-Willi syndrome rare disease asset.
**DAWN to Servier, $2.5 billion.** Oncology bispecific platform, French acquirer.
**RAPT to GSK, $2.2 billion.** Immunology and inflammation pipeline.
**KALV to Chiesi, $1.9 billion.** Hereditary angioedema oral therapy, Italian acquirer.
**ESPR to ARCHIMED, $1.1 billion.** Cardiovascular commercial NEXLETOL franchise.

68 days ago • u/Complex-Jello-2031 • r/stockstobuytoday • drop_a_stock_you_think_everyone_should_buy • C

**The 2026 takeout scorecard, 10 deals, $41.6B**
New deal today
This is what consolidation looks like when it is real. Every one of these names was on the radar before the deal hit.
**CNTA to Lilly, $7.8 billion.** Radiopharmaceutical platform.
**OGN to Sun Pharma, $6.8 billion.** Women's health and biosimilars commercial portfolio, India-based acquirer.
**TERN to Merck, $6.7 billion.** Oral GLP-1 obesity asset.
**APLS to Biogen, $5.6 billion upfront.** Complement platform with SYFOVRE in geographic atrophy and EMPAVELI in PNH.
**CPRX to Angelini Pharma, $4.1 billion.** Rare disease commercial portfolio.
**SLNO to Neurocrine, $2.9 billion.** Prader-Willi syndrome rare disease asset.
**DAWN to Servier, $2.5 billion.** Oncology bispecific platform, French acquirer.
**RAPT to GSK, $2.2 billion.** Immunology and inflammation pipeline.
**KALV to Chiesi, $1.9 billion.** Hereditary angioedema oral therapy, Italian acquirer.
**ESPR to ARCHIMED, $1.1 billion.** Cardiovascular commercial NEXLETOL franchise.

Share